Kapruvia
- Prescription status not stated
- Everything that fits nowhere else, such as contrast media
- Active substance
- Difelikefalin
- Made by
- Vifor Fresenius Medical Care Renal Pharma France
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1).
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (Korsuva). It describes the substance, not this exact product.
KORSUVA is a kappa opioid receptor (KOR) agonist.
The relevance of KOR activation to therapeutic effectiveness is not known.
Difelikefalin is not metabolized by cytochrome P450 (CYP) enzymes CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP2D6 or CYP3A observed in human hepatic microsomes or hepatocytes, in vitro.
Following administration of difelikefalin to HD patients, 11% of the dosage was excreted in urine, 59% in feces, and 20% in dialysate fluid.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-08-26
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | Vifor Fresenius Medical Care Renal Pharma France |
|---|---|
| Active substance | Difelikefalin |
| Used in | Everything that fits nowhere else, such as contrast media |
| Classification | V03AX · Everything that fits nowhere else, such as contrast media |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2022-04-25 |
| Last updated by the regulator | 2026-06-01 |
| EMA product number | EMEA/H/C/005612 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).